Business, energy, technology, markets and global industry news from Business News Today

Alzheimer’s disease

PharmaDeviceNews Alzheimer’s disease
Representative image of brain-targeted drug discovery and AI-designed molecular structures, highlighting the promise of next-generation NLRP3 inhibitors like ISM8969 in treating CNS diseases.
Pharma & Biotech

Insilico, Hygtia Therapeutics to co-develop brain-penetrant NLRP3 inhibitor ISM8969 for CNS diseases

Clinical-stage biotechnology company Insilico Medicine (HKEX: 3696) and Hygtia Therapeutics, a Shenzhen Pengfu Fund–backed startup under Fosun Health Capital, have entered into an exclusive co-development and licensing agreement to jointly advance ISM8969, a novel brain-penetrant NLRP3 inhibitor for central nervous system diseases. The deal grants 50-50 worldwide rights to both companies, with Insilico eligible to

Read More
Representative image illustrating intracellular drug delivery into neurons, reflecting how Mercury Bio Inc. and Meta‑Flux are exploring AI‑guided large‑molecule therapies to target Parkinson’s disease and Alzheimer’s disease at the cellular level.
Pharma & Biotech

Meta-Flux and Mercury Bio team up to target intracellular CNS pathways with precision

Mercury Bio Inc., a biotechnology company focused on large-molecule therapeutics, has announced a strategic collaboration with Meta-Flux, a disease simulation company that leverages artificial intelligence, to advance drug discovery programs for Parkinson’s disease and Alzheimer’s disease. The partnership combines Mercury Bio’s proprietary yeast extracellular vesicle (yEV) delivery technology with Meta-Flux’s disease-scale computational modeling platform, with

Read More
Pharma & Biotech

Sanofi’s tau-focused Alzheimer’s deal highlights growing confidence in non-amyloid targets

Sanofi’s $1 billion Alzheimer’s deal with ADEL highlights why tau biology is back in focus and what risks still stand between promise and proof.

Read More
Pharma & Biotech

Lilly’s $40m commitment to IU aims to transform Alzheimer’s research and trials

Eli Lilly and Indiana University are launching a $40M clinical trial and Alzheimer’s research initiative in Indiana. See what it could mean for U.S. pharma.

Read More